nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP2D6—Lomustine—hematologic cancer	0.0414	0.0738	CbGbCtD
Darifenacin—CYP2D6—Idarubicin—hematologic cancer	0.0369	0.0658	CbGbCtD
Darifenacin—CYP2D6—Hydroxyurea—hematologic cancer	0.0314	0.0559	CbGbCtD
Darifenacin—CYP3A4—Bexarotene—hematologic cancer	0.0283	0.0505	CbGbCtD
Darifenacin—CYP2D6—Bortezomib—hematologic cancer	0.0273	0.0487	CbGbCtD
Darifenacin—CYP3A4—Lomustine—hematologic cancer	0.0263	0.0469	CbGbCtD
Darifenacin—CYP3A4—Busulfan—hematologic cancer	0.0263	0.0469	CbGbCtD
Darifenacin—CYP3A4—Thiotepa—hematologic cancer	0.0235	0.0418	CbGbCtD
Darifenacin—CYP2D6—Imatinib—hematologic cancer	0.02	0.0357	CbGbCtD
Darifenacin—CYP3A4—Methoxsalen—hematologic cancer	0.0183	0.0325	CbGbCtD
Darifenacin—CYP2D6—Nilotinib—hematologic cancer	0.0182	0.0324	CbGbCtD
Darifenacin—CYP2D6—Vinorelbine—hematologic cancer	0.018	0.0321	CbGbCtD
Darifenacin—CYP3A4—Bortezomib—hematologic cancer	0.0174	0.0309	CbGbCtD
Darifenacin—CYP3A4—Daunorubicin—hematologic cancer	0.0166	0.0296	CbGbCtD
Darifenacin—CYP3A4—Cytarabine—hematologic cancer	0.0147	0.0261	CbGbCtD
Darifenacin—CYP3A4—Teniposide—hematologic cancer	0.0144	0.0257	CbGbCtD
Darifenacin—CYP3A4—Ifosfamide—hematologic cancer	0.0133	0.0237	CbGbCtD
Darifenacin—CYP3A4—Imatinib—hematologic cancer	0.0127	0.0227	CbGbCtD
Darifenacin—CYP3A4—Ruxolitinib—hematologic cancer	0.012	0.0213	CbGbCtD
Darifenacin—CYP3A4—Nilotinib—hematologic cancer	0.0116	0.0206	CbGbCtD
Darifenacin—CYP3A4—Vinorelbine—hematologic cancer	0.0115	0.0204	CbGbCtD
Darifenacin—CYP2D6—Vinblastine—hematologic cancer	0.0111	0.0198	CbGbCtD
Darifenacin—CYP3A4—Triamcinolone—hematologic cancer	0.0105	0.0187	CbGbCtD
Darifenacin—CYP3A4—Dasatinib—hematologic cancer	0.0102	0.0182	CbGbCtD
Darifenacin—CYP3A4—Mitoxantrone—hematologic cancer	0.0101	0.018	CbGbCtD
Darifenacin—CYP3A4—Betamethasone—hematologic cancer	0.009	0.016	CbGbCtD
Darifenacin—CYP3A4—Prednisolone—hematologic cancer	0.00888	0.0158	CbGbCtD
Darifenacin—CYP3A4—Prednisone—hematologic cancer	0.00838	0.0149	CbGbCtD
Darifenacin—CYP2D6—Dexamethasone—hematologic cancer	0.00823	0.0147	CbGbCtD
Darifenacin—CYP3A4—Irinotecan—hematologic cancer	0.00795	0.0142	CbGbCtD
Darifenacin—CYP3A4—Vinblastine—hematologic cancer	0.00707	0.0126	CbGbCtD
Darifenacin—CYP3A4—Vincristine—hematologic cancer	0.00695	0.0124	CbGbCtD
Darifenacin—CYP2D6—Doxorubicin—hematologic cancer	0.00683	0.0122	CbGbCtD
Darifenacin—CYP3A4—Etoposide—hematologic cancer	0.00637	0.0113	CbGbCtD
Darifenacin—CYP3A4—Dexamethasone—hematologic cancer	0.00523	0.00932	CbGbCtD
Darifenacin—CYP3A4—Doxorubicin—hematologic cancer	0.00434	0.00774	CbGbCtD
Darifenacin—Clotrimazole—ABCC3—hematologic cancer	0.000379	0.52	CrCbGaD
Darifenacin—Fexofenadine—ABCB1—hematologic cancer	9.92e-05	0.136	CrCbGaD
Darifenacin—Clotrimazole—ABCB1—hematologic cancer	7.67e-05	0.105	CrCbGaD
Darifenacin—Loss of consciousness—Prednisone—hematologic cancer	7.48e-05	0.000212	CcSEcCtD
Darifenacin—Nausea—Carmustine—hematologic cancer	7.45e-05	0.000211	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—hematologic cancer	7.42e-05	0.00021	CcSEcCtD
Darifenacin—Vomiting—Mitoxantrone—hematologic cancer	7.41e-05	0.00021	CcSEcCtD
Darifenacin—Vomiting—Irinotecan—hematologic cancer	7.41e-05	0.00021	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—hematologic cancer	7.4e-05	0.000209	CcSEcCtD
Darifenacin—Nausea—Alitretinoin—hematologic cancer	7.38e-05	0.000209	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—hematologic cancer	7.37e-05	0.000208	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—hematologic cancer	7.37e-05	0.000208	CcSEcCtD
Darifenacin—Hypertension—Prednisone—hematologic cancer	7.35e-05	0.000208	CcSEcCtD
Darifenacin—Rash—Mitoxantrone—hematologic cancer	7.35e-05	0.000208	CcSEcCtD
Darifenacin—Rash—Irinotecan—hematologic cancer	7.35e-05	0.000208	CcSEcCtD
Darifenacin—Dermatitis—Irinotecan—hematologic cancer	7.34e-05	0.000208	CcSEcCtD
Darifenacin—Dermatitis—Mitoxantrone—hematologic cancer	7.34e-05	0.000208	CcSEcCtD
Darifenacin—Headache—Mitoxantrone—hematologic cancer	7.3e-05	0.000207	CcSEcCtD
Darifenacin—Headache—Irinotecan—hematologic cancer	7.3e-05	0.000207	CcSEcCtD
Darifenacin—Nausea—Ifosfamide—hematologic cancer	7.29e-05	0.000206	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Betamethasone—hematologic cancer	7.27e-05	0.000206	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	7.27e-05	0.000206	CcSEcCtD
Darifenacin—Arthralgia—Prednisone—hematologic cancer	7.25e-05	0.000205	CcSEcCtD
Darifenacin—Feeling abnormal—Triamcinolone—hematologic cancer	7.25e-05	0.000205	CcSEcCtD
Darifenacin—Diarrhoea—Cisplatin—hematologic cancer	7.24e-05	0.000205	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—hematologic cancer	7.23e-05	0.000205	CcSEcCtD
Darifenacin—Vomiting—Gemcitabine—hematologic cancer	7.22e-05	0.000204	CcSEcCtD
Darifenacin—Insomnia—Betamethasone—hematologic cancer	7.22e-05	0.000204	CcSEcCtD
Darifenacin—Insomnia—Dexamethasone—hematologic cancer	7.22e-05	0.000204	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	7.2e-05	0.000204	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—hematologic cancer	7.16e-05	0.000203	CcSEcCtD
Darifenacin—Rash—Gemcitabine—hematologic cancer	7.16e-05	0.000202	CcSEcCtD
Darifenacin—Dermatitis—Gemcitabine—hematologic cancer	7.15e-05	0.000202	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—hematologic cancer	7.15e-05	0.000202	CcSEcCtD
Darifenacin—Hypersensitivity—Etoposide—hematologic cancer	7.14e-05	0.000202	CcSEcCtD
Darifenacin—Headache—Gemcitabine—hematologic cancer	7.11e-05	0.000201	CcSEcCtD
Darifenacin—Nausea—Vincristine—hematologic cancer	7.11e-05	0.000201	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—hematologic cancer	7.1e-05	0.000201	CcSEcCtD
Darifenacin—Hypersensitivity—Prednisolone—hematologic cancer	7.05e-05	0.000199	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—hematologic cancer	7.03e-05	0.000199	CcSEcCtD
Darifenacin—Dyspepsia—Dexamethasone—hematologic cancer	7.02e-05	0.000199	CcSEcCtD
Darifenacin—Dyspepsia—Betamethasone—hematologic cancer	7.02e-05	0.000199	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—hematologic cancer	6.99e-05	0.000198	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—hematologic cancer	6.97e-05	0.000197	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—hematologic cancer	6.97e-05	0.000197	CcSEcCtD
Darifenacin—Asthenia—Etoposide—hematologic cancer	6.96e-05	0.000197	CcSEcCtD
Darifenacin—Anaphylactic shock—Prednisone—hematologic cancer	6.95e-05	0.000197	CcSEcCtD
Darifenacin—Oedema—Prednisone—hematologic cancer	6.95e-05	0.000197	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—hematologic cancer	6.94e-05	0.000196	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—hematologic cancer	6.94e-05	0.000196	CcSEcCtD
Darifenacin—Nausea—Irinotecan—hematologic cancer	6.92e-05	0.000196	CcSEcCtD
Darifenacin—Nausea—Mitoxantrone—hematologic cancer	6.92e-05	0.000196	CcSEcCtD
Darifenacin—Infection—Prednisone—hematologic cancer	6.9e-05	0.000195	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—hematologic cancer	6.9e-05	0.000195	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.89e-05	0.000195	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.89e-05	0.000195	CcSEcCtD
Darifenacin—Back pain—Methotrexate—hematologic cancer	6.88e-05	0.000195	CcSEcCtD
Darifenacin—Pruritus—Etoposide—hematologic cancer	6.86e-05	0.000194	CcSEcCtD
Darifenacin—Shock—Prednisone—hematologic cancer	6.84e-05	0.000193	CcSEcCtD
Darifenacin—Pain—Dexamethasone—hematologic cancer	6.82e-05	0.000193	CcSEcCtD
Darifenacin—Pain—Betamethasone—hematologic cancer	6.82e-05	0.000193	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—hematologic cancer	6.82e-05	0.000193	CcSEcCtD
Darifenacin—Nervous system disorder—Prednisone—hematologic cancer	6.82e-05	0.000193	CcSEcCtD
Darifenacin—Tachycardia—Prednisone—hematologic cancer	6.78e-05	0.000192	CcSEcCtD
Darifenacin—Skin disorder—Prednisone—hematologic cancer	6.75e-05	0.000191	CcSEcCtD
Darifenacin—Nausea—Gemcitabine—hematologic cancer	6.75e-05	0.000191	CcSEcCtD
Darifenacin—Vomiting—Cisplatin—hematologic cancer	6.73e-05	0.00019	CcSEcCtD
Darifenacin—Hyperhidrosis—Prednisone—hematologic cancer	6.72e-05	0.00019	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—hematologic cancer	6.71e-05	0.00019	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—hematologic cancer	6.7e-05	0.00019	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—hematologic cancer	6.69e-05	0.000189	CcSEcCtD
Darifenacin—Rash—Cisplatin—hematologic cancer	6.67e-05	0.000189	CcSEcCtD
Darifenacin—Dermatitis—Cisplatin—hematologic cancer	6.67e-05	0.000189	CcSEcCtD
Darifenacin—Diarrhoea—Etoposide—hematologic cancer	6.63e-05	0.000188	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—hematologic cancer	6.62e-05	0.000187	CcSEcCtD
Darifenacin—Feeling abnormal—Betamethasone—hematologic cancer	6.58e-05	0.000186	CcSEcCtD
Darifenacin—Feeling abnormal—Dexamethasone—hematologic cancer	6.58e-05	0.000186	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—hematologic cancer	6.56e-05	0.000186	CcSEcCtD
Darifenacin—Fentanyl—ABCB1—hematologic cancer	6.55e-05	0.0899	CrCbGaD
Darifenacin—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.53e-05	0.000185	CcSEcCtD
Darifenacin—Gastrointestinal pain—Betamethasone—hematologic cancer	6.53e-05	0.000185	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—hematologic cancer	6.52e-05	0.000184	CcSEcCtD
Darifenacin—Hypersensitivity—Triamcinolone—hematologic cancer	6.48e-05	0.000183	CcSEcCtD
Darifenacin—Back pain—Epirubicin—hematologic cancer	6.44e-05	0.000182	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—hematologic cancer	6.42e-05	0.000182	CcSEcCtD
Darifenacin—Dizziness—Etoposide—hematologic cancer	6.41e-05	0.000181	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—hematologic cancer	6.38e-05	0.00018	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.33e-05	0.000179	CcSEcCtD
Darifenacin—Dizziness—Prednisolone—hematologic cancer	6.32e-05	0.000179	CcSEcCtD
Darifenacin—Loperamide—ABCB1—hematologic cancer	6.31e-05	0.0866	CrCbGaD
Darifenacin—Asthenia—Triamcinolone—hematologic cancer	6.31e-05	0.000178	CcSEcCtD
Darifenacin—Abdominal pain—Dexamethasone—hematologic cancer	6.31e-05	0.000178	CcSEcCtD
Darifenacin—Abdominal pain—Betamethasone—hematologic cancer	6.31e-05	0.000178	CcSEcCtD
Darifenacin—Nausea—Cisplatin—hematologic cancer	6.29e-05	0.000178	CcSEcCtD
Darifenacin—Insomnia—Prednisone—hematologic cancer	6.29e-05	0.000178	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—hematologic cancer	6.28e-05	0.000177	CcSEcCtD
Darifenacin—Pruritus—Triamcinolone—hematologic cancer	6.22e-05	0.000176	CcSEcCtD
Darifenacin—Cough—Methotrexate—hematologic cancer	6.21e-05	0.000176	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—hematologic cancer	6.2e-05	0.000175	CcSEcCtD
Darifenacin—Vomiting—Etoposide—hematologic cancer	6.17e-05	0.000174	CcSEcCtD
Darifenacin—Dyspepsia—Prednisone—hematologic cancer	6.12e-05	0.000173	CcSEcCtD
Darifenacin—Rash—Etoposide—hematologic cancer	6.11e-05	0.000173	CcSEcCtD
Darifenacin—Dermatitis—Etoposide—hematologic cancer	6.11e-05	0.000173	CcSEcCtD
Darifenacin—Headache—Etoposide—hematologic cancer	6.07e-05	0.000172	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—hematologic cancer	6.07e-05	0.000172	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—hematologic cancer	6.06e-05	0.000171	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—hematologic cancer	6.03e-05	0.000171	CcSEcCtD
Darifenacin—Rash—Prednisolone—hematologic cancer	6.03e-05	0.000171	CcSEcCtD
Darifenacin—Dermatitis—Prednisolone—hematologic cancer	6.02e-05	0.00017	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.02e-05	0.00017	CcSEcCtD
Darifenacin—Headache—Prednisolone—hematologic cancer	5.99e-05	0.000169	CcSEcCtD
Darifenacin—Syncope—Epirubicin—hematologic cancer	5.97e-05	0.000169	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—hematologic cancer	5.96e-05	0.000169	CcSEcCtD
Darifenacin—Constipation—Prednisone—hematologic cancer	5.94e-05	0.000168	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—hematologic cancer	5.89e-05	0.000166	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—hematologic cancer	5.86e-05	0.000166	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—hematologic cancer	5.85e-05	0.000166	CcSEcCtD
Darifenacin—Dizziness—Triamcinolone—hematologic cancer	5.82e-05	0.000164	CcSEcCtD
Darifenacin—Cough—Epirubicin—hematologic cancer	5.81e-05	0.000164	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—hematologic cancer	5.81e-05	0.000164	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—hematologic cancer	5.81e-05	0.000164	CcSEcCtD
Darifenacin—Infection—Methotrexate—hematologic cancer	5.77e-05	0.000163	CcSEcCtD
Darifenacin—Nausea—Etoposide—hematologic cancer	5.76e-05	0.000163	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—hematologic cancer	5.75e-05	0.000163	CcSEcCtD
Darifenacin—Feeling abnormal—Prednisone—hematologic cancer	5.73e-05	0.000162	CcSEcCtD
Darifenacin—Asthenia—Betamethasone—hematologic cancer	5.73e-05	0.000162	CcSEcCtD
Darifenacin—Asthenia—Dexamethasone—hematologic cancer	5.73e-05	0.000162	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—hematologic cancer	5.7e-05	0.000161	CcSEcCtD
Darifenacin—Gastrointestinal pain—Prednisone—hematologic cancer	5.68e-05	0.000161	CcSEcCtD
Darifenacin—Nausea—Prednisolone—hematologic cancer	5.68e-05	0.000161	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—hematologic cancer	5.67e-05	0.00016	CcSEcCtD
Darifenacin—Pruritus—Dexamethasone—hematologic cancer	5.65e-05	0.00016	CcSEcCtD
Darifenacin—Pruritus—Betamethasone—hematologic cancer	5.65e-05	0.00016	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—hematologic cancer	5.64e-05	0.00016	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.63e-05	0.000159	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—hematologic cancer	5.61e-05	0.000159	CcSEcCtD
Darifenacin—Vomiting—Triamcinolone—hematologic cancer	5.59e-05	0.000158	CcSEcCtD
Darifenacin—Rash—Triamcinolone—hematologic cancer	5.55e-05	0.000157	CcSEcCtD
Darifenacin—Dry mouth—Epirubicin—hematologic cancer	5.55e-05	0.000157	CcSEcCtD
Darifenacin—Dermatitis—Triamcinolone—hematologic cancer	5.54e-05	0.000157	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—hematologic cancer	5.53e-05	0.000156	CcSEcCtD
Darifenacin—Headache—Triamcinolone—hematologic cancer	5.51e-05	0.000156	CcSEcCtD
Darifenacin—Abdominal pain—Prednisone—hematologic cancer	5.49e-05	0.000155	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—hematologic cancer	5.48e-05	0.000155	CcSEcCtD
Darifenacin—Diarrhoea—Betamethasone—hematologic cancer	5.46e-05	0.000154	CcSEcCtD
Darifenacin—Diarrhoea—Dexamethasone—hematologic cancer	5.46e-05	0.000154	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—hematologic cancer	5.45e-05	0.000154	CcSEcCtD
Darifenacin—Oedema—Epirubicin—hematologic cancer	5.44e-05	0.000154	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—hematologic cancer	5.44e-05	0.000154	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—hematologic cancer	5.42e-05	0.000153	CcSEcCtD
Darifenacin—Infection—Epirubicin—hematologic cancer	5.4e-05	0.000153	CcSEcCtD
Darifenacin—Cough—Doxorubicin—hematologic cancer	5.38e-05	0.000152	CcSEcCtD
Darifenacin—Shock—Epirubicin—hematologic cancer	5.35e-05	0.000151	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—hematologic cancer	5.33e-05	0.000151	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—hematologic cancer	5.32e-05	0.00015	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—hematologic cancer	5.3e-05	0.00015	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.29e-05	0.00015	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—hematologic cancer	5.28e-05	0.000149	CcSEcCtD
Darifenacin—Dizziness—Betamethasone—hematologic cancer	5.28e-05	0.000149	CcSEcCtD
Darifenacin—Dizziness—Dexamethasone—hematologic cancer	5.28e-05	0.000149	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—hematologic cancer	5.25e-05	0.000149	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—hematologic cancer	5.25e-05	0.000149	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—hematologic cancer	5.25e-05	0.000148	CcSEcCtD
Darifenacin—Nausea—Triamcinolone—hematologic cancer	5.22e-05	0.000148	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.21e-05	0.000147	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—hematologic cancer	5.18e-05	0.000146	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—hematologic cancer	5.16e-05	0.000146	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—hematologic cancer	5.13e-05	0.000145	CcSEcCtD
Darifenacin—Hypersensitivity—Prednisone—hematologic cancer	5.12e-05	0.000145	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—hematologic cancer	5.11e-05	0.000145	CcSEcCtD
Darifenacin—Vomiting—Dexamethasone—hematologic cancer	5.07e-05	0.000143	CcSEcCtD
Darifenacin—Vomiting—Betamethasone—hematologic cancer	5.07e-05	0.000143	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—hematologic cancer	5.07e-05	0.000143	CcSEcCtD
Darifenacin—Rash—Dexamethasone—hematologic cancer	5.03e-05	0.000142	CcSEcCtD
Darifenacin—Rash—Betamethasone—hematologic cancer	5.03e-05	0.000142	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—hematologic cancer	5.03e-05	0.000142	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—hematologic cancer	5.03e-05	0.000142	CcSEcCtD
Darifenacin—Dermatitis—Betamethasone—hematologic cancer	5.03e-05	0.000142	CcSEcCtD
Darifenacin—Dermatitis—Dexamethasone—hematologic cancer	5.03e-05	0.000142	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.01e-05	0.000142	CcSEcCtD
Darifenacin—Headache—Betamethasone—hematologic cancer	5e-05	0.000141	CcSEcCtD
Darifenacin—Headache—Dexamethasone—hematologic cancer	5e-05	0.000141	CcSEcCtD
Darifenacin—Infection—Doxorubicin—hematologic cancer	5e-05	0.000141	CcSEcCtD
Darifenacin—Asthenia—Prednisone—hematologic cancer	4.99e-05	0.000141	CcSEcCtD
Darifenacin—Pain—Methotrexate—hematologic cancer	4.97e-05	0.00014	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.95e-05	0.00014	CcSEcCtD
Darifenacin—Shock—Doxorubicin—hematologic cancer	4.95e-05	0.00014	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—hematologic cancer	4.93e-05	0.000139	CcSEcCtD
Darifenacin—Pruritus—Prednisone—hematologic cancer	4.92e-05	0.000139	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—hematologic cancer	4.92e-05	0.000139	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—hematologic cancer	4.91e-05	0.000139	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—hematologic cancer	4.89e-05	0.000138	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—hematologic cancer	4.86e-05	0.000137	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—hematologic cancer	4.85e-05	0.000137	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—hematologic cancer	4.83e-05	0.000137	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—hematologic cancer	4.79e-05	0.000135	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—hematologic cancer	4.78e-05	0.000135	CcSEcCtD
Darifenacin—Diarrhoea—Prednisone—hematologic cancer	4.76e-05	0.000134	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—hematologic cancer	4.75e-05	0.000134	CcSEcCtD
Darifenacin—Nausea—Dexamethasone—hematologic cancer	4.74e-05	0.000134	CcSEcCtD
Darifenacin—Nausea—Betamethasone—hematologic cancer	4.74e-05	0.000134	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.69e-05	0.000133	CcSEcCtD
Darifenacin—Pain—Epirubicin—hematologic cancer	4.65e-05	0.000131	CcSEcCtD
Darifenacin—Constipation—Epirubicin—hematologic cancer	4.65e-05	0.000131	CcSEcCtD
Darifenacin—Dizziness—Prednisone—hematologic cancer	4.6e-05	0.00013	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—hematologic cancer	4.59e-05	0.00013	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.58e-05	0.00013	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—hematologic cancer	4.55e-05	0.000129	CcSEcCtD
Darifenacin—Methadone—ABCB1—hematologic cancer	4.49e-05	0.0617	CrCbGaD
Darifenacin—Dyspnoea—Doxorubicin—hematologic cancer	4.48e-05	0.000127	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—hematologic cancer	4.48e-05	0.000127	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—hematologic cancer	4.47e-05	0.000126	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—hematologic cancer	4.44e-05	0.000126	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—hematologic cancer	4.43e-05	0.000125	CcSEcCtD
Darifenacin—Vomiting—Prednisone—hematologic cancer	4.42e-05	0.000125	CcSEcCtD
Darifenacin—Rash—Prednisone—hematologic cancer	4.38e-05	0.000124	CcSEcCtD
Darifenacin—Dermatitis—Prednisone—hematologic cancer	4.38e-05	0.000124	CcSEcCtD
Darifenacin—Headache—Prednisone—hematologic cancer	4.35e-05	0.000123	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.34e-05	0.000123	CcSEcCtD
Darifenacin—Pain—Doxorubicin—hematologic cancer	4.3e-05	0.000122	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—hematologic cancer	4.3e-05	0.000122	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—hematologic cancer	4.3e-05	0.000122	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—hematologic cancer	4.28e-05	0.000121	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—hematologic cancer	4.17e-05	0.000118	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—hematologic cancer	4.14e-05	0.000117	CcSEcCtD
Darifenacin—Nausea—Prednisone—hematologic cancer	4.13e-05	0.000117	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.11e-05	0.000116	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—hematologic cancer	4.11e-05	0.000116	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—hematologic cancer	4e-05	0.000113	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—hematologic cancer	3.98e-05	0.000112	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—hematologic cancer	3.97e-05	0.000112	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—hematologic cancer	3.9e-05	0.00011	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—hematologic cancer	3.85e-05	0.000109	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—hematologic cancer	3.84e-05	0.000109	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—hematologic cancer	3.72e-05	0.000105	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—hematologic cancer	3.71e-05	0.000105	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—hematologic cancer	3.69e-05	0.000104	CcSEcCtD
Darifenacin—Rash—Methotrexate—hematologic cancer	3.66e-05	0.000104	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—hematologic cancer	3.66e-05	0.000103	CcSEcCtD
Darifenacin—Headache—Methotrexate—hematologic cancer	3.64e-05	0.000103	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—hematologic cancer	3.61e-05	0.000102	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—hematologic cancer	3.59e-05	0.000102	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—hematologic cancer	3.56e-05	0.000101	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—hematologic cancer	3.46e-05	9.77e-05	CcSEcCtD
Darifenacin—Nausea—Methotrexate—hematologic cancer	3.45e-05	9.76e-05	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—hematologic cancer	3.44e-05	9.73e-05	CcSEcCtD
Darifenacin—Rash—Epirubicin—hematologic cancer	3.43e-05	9.69e-05	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—hematologic cancer	3.42e-05	9.68e-05	CcSEcCtD
Darifenacin—Headache—Epirubicin—hematologic cancer	3.41e-05	9.63e-05	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—hematologic cancer	3.33e-05	9.4e-05	CcSEcCtD
Darifenacin—Nausea—Epirubicin—hematologic cancer	3.23e-05	9.13e-05	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—hematologic cancer	3.2e-05	9.04e-05	CcSEcCtD
Darifenacin—Rash—Doxorubicin—hematologic cancer	3.17e-05	8.97e-05	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—hematologic cancer	3.17e-05	8.96e-05	CcSEcCtD
Darifenacin—Headache—Doxorubicin—hematologic cancer	3.15e-05	8.91e-05	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—hematologic cancer	2.99e-05	8.45e-05	CcSEcCtD
Darifenacin—CYP2D6—Metabolism—GSTP1—hematologic cancer	6.84e-06	8.1e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ESR1—hematologic cancer	6.84e-06	8.1e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL2—hematologic cancer	6.83e-06	8.1e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—FN1—hematologic cancer	6.82e-06	8.08e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—HRAS—hematologic cancer	6.8e-06	8.06e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—hematologic cancer	6.8e-06	8.06e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTR—hematologic cancer	6.78e-06	8.04e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCG2—hematologic cancer	6.78e-06	8.04e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—hematologic cancer	6.77e-06	8.03e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BAD—hematologic cancer	6.76e-06	8.01e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	6.76e-06	8.01e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—FN1—hematologic cancer	6.75e-06	8e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	6.74e-06	7.99e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BAD—hematologic cancer	6.74e-06	7.99e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	6.69e-06	7.93e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	6.68e-06	7.92e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	6.67e-06	7.91e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	6.67e-06	7.91e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BAD—hematologic cancer	6.67e-06	7.91e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCND1—hematologic cancer	6.66e-06	7.89e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ENO2—hematologic cancer	6.65e-06	7.88e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—JUN—hematologic cancer	6.65e-06	7.88e-05	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	6.61e-06	7.84e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	6.61e-06	7.83e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CD80—hematologic cancer	6.56e-06	7.77e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CASP3—hematologic cancer	6.55e-06	7.77e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KIT—hematologic cancer	6.55e-06	7.76e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	6.55e-06	7.76e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	6.55e-06	7.76e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL2—hematologic cancer	6.54e-06	7.75e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CD80—hematologic cancer	6.54e-06	7.75e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	6.52e-06	7.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KIT—hematologic cancer	6.52e-06	7.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	6.52e-06	7.73e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—hematologic cancer	6.51e-06	7.72e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3R1—hematologic cancer	6.48e-06	7.68e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CD80—hematologic cancer	6.47e-06	7.67e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ABCB1—hematologic cancer	6.47e-06	7.67e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KIT—hematologic cancer	6.46e-06	7.66e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	6.46e-06	7.66e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	6.46e-06	7.66e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.45e-06	7.64e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	6.44e-06	7.64e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	6.43e-06	7.62e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PTEN—hematologic cancer	6.43e-06	7.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	6.41e-06	7.6e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—hematologic cancer	6.38e-06	7.56e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—JUN—hematologic cancer	6.36e-06	7.54e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	6.35e-06	7.52e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SDC1—hematologic cancer	6.3e-06	7.47e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	6.29e-06	7.45e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NCOR1—hematologic cancer	6.28e-06	7.45e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—hematologic cancer	6.28e-06	7.45e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	6.27e-06	7.43e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	6.27e-06	7.43e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	6.25e-06	7.41e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CREB1—hematologic cancer	6.23e-06	7.38e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CREB1—hematologic cancer	6.21e-06	7.36e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	6.19e-06	7.33e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	6.17e-06	7.31e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PTEN—hematologic cancer	6.16e-06	7.3e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BRAF—hematologic cancer	6.15e-06	7.29e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CREB1—hematologic cancer	6.15e-06	7.29e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BRAF—hematologic cancer	6.13e-06	7.27e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EP300—hematologic cancer	6.13e-06	7.27e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL2—hematologic cancer	6.1e-06	7.23e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6R—hematologic cancer	6.08e-06	7.2e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL2—hematologic cancer	6.08e-06	7.2e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BRAF—hematologic cancer	6.07e-06	7.2e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	6.07e-06	7.19e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6R—hematologic cancer	6.06e-06	7.18e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	6.05e-06	7.17e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	6.02e-06	7.14e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL2—hematologic cancer	6.02e-06	7.13e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	6e-06	7.12e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6R—hematologic cancer	6e-06	7.11e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	5.99e-06	7.1e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CB—hematologic cancer	5.98e-06	7.09e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SRC—hematologic cancer	5.96e-06	7.07e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EP300—hematologic cancer	5.87e-06	6.96e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	5.81e-06	6.88e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	5.79e-06	6.87e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	5.77e-06	6.84e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	5.75e-06	6.82e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—hematologic cancer	5.75e-06	6.81e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	5.74e-06	6.8e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NRAS—hematologic cancer	5.73e-06	6.8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	5.72e-06	6.78e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SRC—hematologic cancer	5.71e-06	6.77e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.7e-06	6.76e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	5.68e-06	6.73e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	5.68e-06	6.73e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	5.63e-06	6.68e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	5.63e-06	6.67e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	5.62e-06	6.66e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	5.56e-06	6.59e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	5.56e-06	6.59e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—MTHFR—hematologic cancer	5.55e-06	6.58e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—FGF2—hematologic cancer	5.51e-06	6.53e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—hematologic cancer	5.5e-06	6.52e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—FGF2—hematologic cancer	5.49e-06	6.51e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	5.49e-06	6.51e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NRAS—hematologic cancer	5.49e-06	6.51e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—FGF2—hematologic cancer	5.44e-06	6.45e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	5.43e-06	6.44e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	5.42e-06	6.42e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	5.36e-06	6.36e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CD44—hematologic cancer	5.36e-06	6.35e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NQO1—hematologic cancer	5.36e-06	6.35e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—hematologic cancer	5.34e-06	6.33e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	5.33e-06	6.32e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—JAK2—hematologic cancer	5.28e-06	6.26e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—JAK2—hematologic cancer	5.26e-06	6.24e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	5.26e-06	6.23e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—JAK2—hematologic cancer	5.21e-06	6.18e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	5.18e-06	6.13e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTEN—hematologic cancer	5.17e-06	6.12e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	5.16e-06	6.12e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MDM2—hematologic cancer	5.15e-06	6.11e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MDM2—hematologic cancer	5.14e-06	6.09e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—hematologic cancer	5.12e-06	6.06e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	5.11e-06	6.06e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	5.1e-06	6.05e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MDM2—hematologic cancer	5.09e-06	6.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYCS—hematologic cancer	5.07e-06	6.01e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	5.04e-06	5.97e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MTOR—hematologic cancer	5.02e-06	5.94e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	5.02e-06	5.94e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MTOR—hematologic cancer	5e-06	5.93e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	5e-06	5.93e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	4.95e-06	5.87e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MTOR—hematologic cancer	4.95e-06	5.87e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KRAS—hematologic cancer	4.94e-06	5.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—EP300—hematologic cancer	4.93e-06	5.84e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	4.79e-06	5.68e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	4.77e-06	5.66e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	4.73e-06	5.6e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KRAS—hematologic cancer	4.73e-06	5.6e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	4.71e-06	5.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	4.69e-06	5.56e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—hematologic cancer	4.67e-06	5.53e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	4.66e-06	5.52e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	4.65e-06	5.51e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	4.64e-06	5.5e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—hematologic cancer	4.61e-06	5.47e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL2—hematologic cancer	4.61e-06	5.46e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—hematologic cancer	4.6e-06	5.45e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	4.6e-06	5.45e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL2—hematologic cancer	4.59e-06	5.44e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—hematologic cancer	4.58e-06	5.43e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—hematologic cancer	4.57e-06	5.41e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—hematologic cancer	4.55e-06	5.4e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL2—hematologic cancer	4.55e-06	5.39e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	4.53e-06	5.37e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—hematologic cancer	4.52e-06	5.36e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—hematologic cancer	4.49e-06	5.32e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—JUN—hematologic cancer	4.48e-06	5.31e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—hematologic cancer	4.48e-06	5.31e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.47e-06	5.3e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—JUN—hematologic cancer	4.47e-06	5.29e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—hematologic cancer	4.43e-06	5.25e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—JUN—hematologic cancer	4.42e-06	5.24e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—hematologic cancer	4.39e-06	5.2e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	4.34e-06	5.15e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	4.34e-06	5.15e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTEN—hematologic cancer	4.33e-06	5.14e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	4.33e-06	5.13e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CREBBP—hematologic cancer	4.33e-06	5.13e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTEN—hematologic cancer	4.32e-06	5.12e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	4.29e-06	5.08e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTEN—hematologic cancer	4.28e-06	5.07e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	4.24e-06	5.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.23e-06	5.02e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	4.23e-06	5.01e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	4.23e-06	5.01e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	4.21e-06	5e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—hematologic cancer	4.2e-06	4.98e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HRAS—hematologic cancer	4.2e-06	4.97e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	4.19e-06	4.96e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	4.17e-06	4.95e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EP300—hematologic cancer	4.13e-06	4.9e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EP300—hematologic cancer	4.12e-06	4.88e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.11e-06	4.87e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.11e-06	4.87e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CD—hematologic cancer	4.1e-06	4.86e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EP300—hematologic cancer	4.08e-06	4.84e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—hematologic cancer	4.05e-06	4.8e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SRC—hematologic cancer	4.02e-06	4.76e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HRAS—hematologic cancer	4.02e-06	4.76e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—hematologic cancer	4.02e-06	4.76e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SRC—hematologic cancer	4.01e-06	4.75e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SRC—hematologic cancer	3.97e-06	4.7e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	3.91e-06	4.64e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	3.9e-06	4.63e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—hematologic cancer	3.88e-06	4.59e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.87e-06	4.59e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NRAS—hematologic cancer	3.87e-06	4.58e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	3.86e-06	4.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—hematologic cancer	3.86e-06	4.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NRAS—hematologic cancer	3.85e-06	4.57e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—hematologic cancer	3.85e-06	4.56e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—hematologic cancer	3.83e-06	4.54e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NRAS—hematologic cancer	3.82e-06	4.52e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—hematologic cancer	3.7e-06	4.39e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	3.7e-06	4.39e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	3.69e-06	4.38e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	3.66e-06	4.33e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—hematologic cancer	3.64e-06	4.32e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.63e-06	4.3e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—hematologic cancer	3.6e-06	4.27e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	3.59e-06	4.26e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—hematologic cancer	3.59e-06	4.26e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	3.58e-06	4.25e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CB—hematologic cancer	3.57e-06	4.24e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—hematologic cancer	3.56e-06	4.21e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—hematologic cancer	3.55e-06	4.2e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	3.55e-06	4.2e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KRAS—hematologic cancer	3.33e-06	3.94e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KRAS—hematologic cancer	3.32e-06	3.93e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KRAS—hematologic cancer	3.29e-06	3.89e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTEN—hematologic cancer	3.09e-06	3.66e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	3.06e-06	3.62e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.05e-06	3.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	3.05e-06	3.61e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	3.02e-06	3.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—hematologic cancer	2.98e-06	3.53e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.96e-06	3.51e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—hematologic cancer	2.95e-06	3.49e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—EP300—hematologic cancer	2.95e-06	3.49e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—hematologic cancer	2.92e-06	3.46e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.83e-06	3.35e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.83e-06	3.35e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HRAS—hematologic cancer	2.82e-06	3.34e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HRAS—hematologic cancer	2.79e-06	3.31e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—hematologic cancer	2.71e-06	3.21e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—hematologic cancer	2.7e-06	3.2e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.68e-06	3.18e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—hematologic cancer	2.67e-06	3.17e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—hematologic cancer	2.65e-06	3.14e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.53e-06	3e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—hematologic cancer	2.5e-06	2.96e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—hematologic cancer	2.49e-06	2.95e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—hematologic cancer	2.47e-06	2.92e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.34e-06	2.77e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.18e-06	2.58e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTEN—hematologic cancer	2.02e-06	2.39e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—EP300—hematologic cancer	1.93e-06	2.28e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—hematologic cancer	1.78e-06	2.11e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.42e-06	1.69e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—hematologic cancer	1.16e-06	1.38e-05	CbGpPWpGaD
